Summary of Key Information:

Reporting Period: Quarter and Half Year ended September 30, 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Financial Results

Audit Opinion:

Unmodified conclusion by statutory auditors M/s. Singhi & Co. on both standalone and consolidated financial results.

Key Financial Highlights [Amounts in ₹ lakhs]:

Standalone Results:

For Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹34,126.66
  • Total Income: ₹36,989.74
  • Net Profit: ₹3,675.93
  • EPS: ₹6.14 (Basic & Diluted)

For Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹64,543.79
  • Total Income: ₹68,411.59
  • Net Profit: ₹4,869.65
  • EPS: ₹8.13 (Basic & Diluted)

Comparative Performance (Quarter):

  • Revenue growth: 14.3% YoY (₹34,126.66 vs ₹29,845.86 in Q2 FY26)
  • Net Profit growth: 444% YoY (₹3,675.93 vs ₹690.80 in Q2 FY26)

Consolidated Results:

For Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹34,126.66
  • Total Income: ₹35,902.24
  • Net Profit: ₹2,859.41
  • EPS: ₹4.77 (Basic & Diluted)

For Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹64,543.79
  • Total Income: ₹66,502.21
  • Net Profit: ₹3,181.85
  • EPS: ₹5.31 (Basic & Diluted)

Balance Sheet Highlights (Standalone as of September 30, 2026):

  • Property, plant and equipment: ₹69,659.91 lakhs
  • Capital work in progress: ₹19,612.41 lakhs
  • Cash and cash equivalents: ₹2,392.59 lakhs
  • Total borrowings: ₹27,705.92 lakhs (Non-current: ₹10,125.45 + Current: ₹17,580.47)
  • Other Equity: ₹1,63,313.53 lakhs

Corporate Actions:

The Scheme of Amalgamation between Dhanuka Laboratories Limited (Transferor Company) and Orchid Pharma Limited (Transferee Company) was sanctioned by NCLT Chennai vide order dated June 05, 2026. The Scheme had an appointed date of April 01, 2024 and became effective on July 10, 2026 upon filing with ROC Chennai. All comparative periods have been restated to give effect to the amalgamation.

During the quarter, the business of Synmedic Laboratories (partnership firm) was transferred to the Company on a going concern basis through slump sale effective July 3, 2026.

Other Significant Information:

QIP Utilization: Net proceeds of ₹39,454 lakhs raised through QIP (June 2023) were fully utilized as of September 30, 2026:

  • Investment in subsidiary (OBPL) for Jammu facility: ₹13,500 lakhs
  • Debt repayment: ₹19,546 lakhs
  • Capex for API facility in Alathur: ₹36 lakhs
  • General corporate purposes: ₹6,372 lakhs

Labour Code Provision: The Company recognized an exceptional item of ₹733.29 lakhs in FY26 for incremental estimated liabilities relating to gratuity and leave under the New Labour Codes effective November 21, 2025.

Segment Information: Operations fall under a single pharmaceutical segment.

Entities in Consolidation:

Subsidiaries: Orchid Pharmaceuticals Inc. (USA), Bexel Pharmaceuticals Inc. (USA), Diakron Pharmaceuticals Inc. (USA), Orchid Bio-Pharma Limited, Orchid Pharma Europe GmbH (w.e.f. July 30, 2025)

Associate: Orbion Pharmaceuticals Private Limited (accounted under equity method)